Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 401 - 450 of 1864 results
- The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.
- Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.
- Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.
- Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer.
- Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
- The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver.
- Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
- In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
- A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
- Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
- Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
- Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis.
- Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
- Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.
- A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
- Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.
- Synthesis of glycosylated human tumor necrosis factor alpha coupled with N-acetylneuraminic acid.
- Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
- A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma.
- Identification of a series of highly potent activators of the Nurr1 signaling pathway.
- Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.
- A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
- Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
- Triggering CD40 on endothelial cells contributes to tumor growth.
- Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
- Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
- Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy.
- The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro.
- Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.
- CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge.
- Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions.
- Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
- A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
- A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
- A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
- The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer.
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
- Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
- Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
- Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
- Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.
- Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.
- Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages.
- Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma.
- CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection.
- Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
- CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients.
- Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients.
- Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
- A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.